ITPD910102A1 - Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. - Google Patents

Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.

Info

Publication number
ITPD910102A1
ITPD910102A1 IT000102A ITPD910102A ITPD910102A1 IT PD910102 A1 ITPD910102 A1 IT PD910102A1 IT 000102 A IT000102 A IT 000102A IT PD910102 A ITPD910102 A IT PD910102A IT PD910102 A1 ITPD910102 A1 IT PD910102A1
Authority
IT
Italy
Prior art keywords
biologically active
preparation
active components
microspheres containing
containing biologically
Prior art date
Application number
IT000102A
Other languages
English (en)
Inventor
Luca Benedetti
Lanfranco Callegaro
Aurelio Romeo
Original Assignee
Fidia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Spa filed Critical Fidia Spa
Publication of ITPD910102A0 publication Critical patent/ITPD910102A0/it
Priority to ITPD910102A priority Critical patent/IT1247472B/it
Priority to DE69231507T priority patent/DE69231507T2/de
Priority to AT92401433T priority patent/ATE196991T1/de
Priority to EP99202579A priority patent/EP0979648A3/en
Priority to ES92401433T priority patent/ES2153355T3/es
Priority to EP92401433A priority patent/EP0517565B1/en
Priority to CA002070095A priority patent/CA2070095C/en
Priority to JP4139012A priority patent/JPH07179363A/ja
Publication of ITPD910102A1 publication Critical patent/ITPD910102A1/it
Priority to US08/169,558 priority patent/US6066340A/en
Application granted granted Critical
Publication of IT1247472B publication Critical patent/IT1247472B/it
Priority to US09/231,353 priority patent/US6039970A/en
Priority to GR20000402482T priority patent/GR3034789T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ITPD910102A 1991-05-31 1991-05-31 Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. IT1247472B (it)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ITPD910102A IT1247472B (it) 1991-05-31 1991-05-31 Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
DE69231507T DE69231507T2 (de) 1991-05-31 1992-05-26 Verfahren zur Zubereitung von biologisch aktiven Komponenten enthaltenden Mikrospheren
AT92401433T ATE196991T1 (de) 1991-05-31 1992-05-26 Verfahren zur zubereitung von biologisch aktiven komponenten enthaltenden mikrospheren
EP99202579A EP0979648A3 (en) 1991-05-31 1992-05-26 Microspheres of esters of hyaluronic acid for controlled release of an active
ES92401433T ES2153355T3 (es) 1991-05-31 1992-05-26 Procedimiento para la preparacion de microesferas que contienen compuestos biologicamente activos.
EP92401433A EP0517565B1 (en) 1991-05-31 1992-05-26 Process for the preparation of microspheres containing biologically active components
CA002070095A CA2070095C (en) 1991-05-31 1992-05-29 Microspheres containing biologically-active components, processes for the preparation and uses
JP4139012A JPH07179363A (ja) 1991-05-31 1992-05-29 生物学的に活性な成分を含有するミクロスフェアの製造方法
US08/169,558 US6066340A (en) 1991-05-31 1993-12-20 Process for the preparation of microspheres containing biologically active components
US09/231,353 US6039970A (en) 1991-05-31 1999-01-13 Process for the preparation of microspheres containing biologically active components
GR20000402482T GR3034789T3 (en) 1991-05-31 2000-11-08 Process for the preparation of microspheres containing biologically active components.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITPD910102A IT1247472B (it) 1991-05-31 1991-05-31 Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.

Publications (3)

Publication Number Publication Date
ITPD910102A0 ITPD910102A0 (it) 1991-05-31
ITPD910102A1 true ITPD910102A1 (it) 1992-12-01
IT1247472B IT1247472B (it) 1994-12-17

Family

ID=11389598

Family Applications (1)

Application Number Title Priority Date Filing Date
ITPD910102A IT1247472B (it) 1991-05-31 1991-05-31 Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.

Country Status (9)

Country Link
US (2) US6066340A (it)
EP (2) EP0517565B1 (it)
JP (1) JPH07179363A (it)
AT (1) ATE196991T1 (it)
CA (1) CA2070095C (it)
DE (1) DE69231507T2 (it)
ES (1) ES2153355T3 (it)
GR (1) GR3034789T3 (it)
IT (1) IT1247472B (it)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
IT1263144B (it) * 1993-02-04 1996-08-01 Lanfranco Callegaro Composizioni farmaceutiche comprendenti materiale spugnoso costituito da derivati esterei dell'acido ialuronico in associazione con altre sostanze farmacologicamente attive
JPH0827018A (ja) * 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
WO1996029998A1 (en) * 1995-03-28 1996-10-03 Fidia Advanced Biopolymers S.R.L. Nanospheres comprising a biocompatible polysaccharide
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US7276251B2 (en) * 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
IT1294797B1 (it) 1997-07-28 1999-04-15 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico nella preparazione di biomateriali aventi attivita' emostatica fisica e tamponante
AU3055099A (en) 1998-05-20 1999-12-06 Charna Chemicals Ltd. A pharmaceutical formulation for nasal administration
US6824793B1 (en) 1998-06-01 2004-11-30 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
JP4610735B2 (ja) * 1998-06-01 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ワクチン抗原およびアジュバントの粘膜送達のためのヒアルロン酸ポリマーの使用
ATE481108T1 (de) 1999-02-26 2010-10-15 Novartis Vaccines & Diagnostic Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
AU5624400A (en) * 1999-06-18 2001-01-09 Collaborative Group, Ltd., The Hyaluronic acid film and matrix for sustained gene transfer
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
GB0004827D0 (en) * 2000-02-29 2000-04-19 Quadrant Holdings Cambridge Compositions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
DE10064219B9 (de) * 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
DE60218375D1 (de) * 2001-03-30 2007-04-12 Chisso Corp Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen
FR2825273B1 (fr) * 2001-05-29 2006-11-24 Oreal Composition pour le traitement des signes cutanes du vieillissement
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US7276254B2 (en) * 2002-05-07 2007-10-02 Xerox Corporation Emulsion/aggregation polymeric microspheres for biomedical applications and methods of making same
WO2003099992A2 (en) * 2002-05-17 2003-12-04 Wyeth Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
US20040197264A1 (en) * 2003-04-04 2004-10-07 Alexander Schwarz Microspheres comprising therapeutic and diagnostic radioactive isotopes
ES2226567B1 (es) * 2003-06-20 2006-07-01 Universidad De Santiago De Compostela Nanoparticulas de acido hialuronico.
ES2232287B1 (es) * 2003-07-04 2006-11-01 Advanced In Vitro Cell Technologies, S.L. Nanoparticulas de derivados polioxietilenados.
US8124120B2 (en) * 2003-12-22 2012-02-28 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
ES2246694B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
ES2246695B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
EP2163562B1 (en) 2005-06-21 2013-09-18 XOMA Technology Ltd. IL-1beta binding antibodies and fragments thereof
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
US8747872B2 (en) 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
HRP20141194T1 (hr) 2007-12-20 2015-04-24 Xoma (Us) Llc Postupci lijeäśenja gihta
ITMI20080981A1 (it) * 2008-05-27 2009-11-28 Fidia Advanced Biopolymers Srl Processo per la preparazione di microsfere di polimeri semi-sintetici
JP5722782B2 (ja) 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
BRPI1014031A2 (pt) 2009-06-16 2018-02-20 Univ Michigan Regents vacinas de nanoemulsão
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
GB201017889D0 (en) * 2010-10-22 2010-12-01 Univ Dublin A polymeric nanoparticle
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
WO2014159759A1 (en) 2013-03-13 2014-10-02 Biosphere Medical, Inc. Compositions and associated methods for radioisotope-binding microparticles
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3057991B8 (en) 2013-10-15 2019-09-04 The Scripps Research Institute Chimeric antigen receptor t cell switches and uses thereof
EP3057994B1 (en) 2013-10-15 2020-09-23 The Scripps Research Institute Peptidic chimeric antigen receptor t cell switches and uses thereof
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
WO2016057921A1 (en) 2014-10-10 2016-04-14 Baker Jr James R Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
EP4226937A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2016207730A1 (en) 2015-06-22 2016-12-29 The University Of Oslo Targeting of vaccine antigen to an intracellular compartment
CN105663052B (zh) * 2016-02-05 2019-03-15 舒泰神（北京）生物制药股份有限公司 神经生长因子缓释微球制剂及其制备方法
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
WO2018075807A1 (en) 2016-10-19 2018-04-26 California Institute For Biomedical Research Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
EP3678698A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
CA3103265A1 (en) 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
US20220380487A1 (en) 2019-10-24 2022-12-01 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
KR102296304B1 (ko) 2020-11-30 2021-09-01 조광용 고팽윤성 히알루론산 비드 겔 제조 방법
KR102366394B1 (ko) 2021-01-05 2022-02-23 조광용 고팽윤성 히알루론산 비드 겔
EP4313132A1 (en) 2021-03-31 2024-02-07 Vib Vzw Vaccine compositions for trypanosomatids
CN118251420A (zh) 2021-04-28 2024-06-25 米诺陶治疗公司 人源化嵌合牛抗体和使用方法
EP4514389A1 (en) 2022-04-29 2025-03-05 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
WO2025225629A1 (ja) * 2024-04-23 2025-10-30 株式会社メディラボRfp 経鼻投与用組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4636524A (en) 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
SE8501022L (sv) 1985-03-01 1986-09-02 Pharmacia Ab Format alster och forfarande for dess framstellning
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
WO1987003197A1 (en) * 1985-11-29 1987-06-04 Fisons Plc Pharmaceutical composition including sodium cromoglycate
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
IT1203814B (it) 1986-06-30 1989-02-23 Fidia Farmaceutici Esteri dell'acido alginico
NL8720442A (nl) * 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5108759A (en) * 1987-04-01 1992-04-28 Ranney David F Endothelial envelopment drug carriers
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
JP3187410B2 (ja) * 1989-08-10 2001-07-11 住友製薬株式会社 脳内投与用徐放性製剤
GB2237510B (en) * 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5879359A (en) * 1992-08-03 1999-03-09 Fidia S.P.A. Biodegradable guide channels comprised of esters of hyaluronic acid for use in tissue repair as surgical aids
IT1268955B1 (it) * 1994-03-11 1997-03-18 Fidia Advanced Biopolymers Srl Esteri attivi di polisaccaridi carbossilici
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
EP0907721A1 (en) * 1996-05-28 1999-04-14 Brown University Research Foundation Hyaluronan based biodegradable scaffolds for tissue repair

Also Published As

Publication number Publication date
EP0517565A2 (en) 1992-12-09
ITPD910102A0 (it) 1991-05-31
CA2070095A1 (en) 1992-12-01
ATE196991T1 (de) 2000-11-15
EP0979648A2 (en) 2000-02-16
US6039970A (en) 2000-03-21
DE69231507T2 (de) 2001-05-03
JPH07179363A (ja) 1995-07-18
CA2070095C (en) 2000-04-25
US6066340A (en) 2000-05-23
ES2153355T3 (es) 2001-03-01
IT1247472B (it) 1994-12-17
GR3034789T3 (en) 2001-02-28
DE69231507D1 (de) 2000-11-23
EP0517565B1 (en) 2000-10-18
EP0517565A3 (en) 1992-12-30
EP0979648A3 (en) 2000-10-04

Similar Documents

Publication Publication Date Title
ITPD910102A1 (it) Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
EP0737751A3 (en) Process for the preparation of optically active gamma-substituted-hydroxy-butyric acid esters
FR2710638B1 (fr) Procédé de préparation d'isomères d'acides benzènedicarboxyliques de haute pureté.
KR960702348A (ko) 불포화 카르복실산 에스테르 제조용 촉매 및 그의 사용 방법 (Catalyst and Process for Using for the Preparation of Unsaturated Carboxylic Acid Esters)
EP0608838A3 (en) Method of producing an unsaturated carboxylic acid.
EP0915077A4 (en) POLYMERIZABLE ADAMANTAN DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
ATE90570T1 (de) Verbesserte formulierungen mit kontrollierter abgabe.
ITRM920761A1 (it) Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
ES2055209T3 (es) Preparaciones conteniendo esteres del acido (met)acrilico que contienen grupos carbonamidas para su uso como componentes adhesivos para el tratamiento de materiales con colageno en medicina, asi como la fabricacion de estas preparaciones.
ATE137795T1 (de) Verbessertes träger- und freisetzungssystem von riechstoffen für die wäschebehandlung
EP0647653A3 (en) Improved process for the production of saccharide fatty acid polyesters by transesterification.
FR2602229B1 (fr) Procede de preparation d'esters d'acides carboxyliques insatures
AU3674589A (en) Skin- or hair-care compositions containing silica and carboxylic acid esters
BR8802816A (pt) Derivados do acido(2-ciano-9-oximinoacetil)-aminico,processo para sua preparacao,composicoes praguicidas,processos para combater pragas e para a preparacao de composicoes
FI935712L (fi) Menetelmä optisesti aktiivisten transglysidihappoestereiden entsyaattiseksi valmistamiseksi
PT96241A (pt) Processo para a preparacao de um desodorizante para estrume a base de ester de acido undecilenico
EP0294668A3 (en) (2-cyano-2-oximinoacetyl)-amino acid derivatives
FR2701944B1 (fr) Procédé d'hydroxycarbonylation de lactones en acides dicarboxyliques aliphatiques.
ATE110720T1 (de) Verfahren zur herstellung von 2-mercapto-4-methyl-1,3-thiazol-5-yl-essigsäure und deren ester.
EP0344791A3 (en) Process for the enzymatic resolution of the optical isomers of racemic ester derivatives of 3-mercapto-2-alkyl-propionic acid
EP0640582A3 (de) Verfahren zur Herstellung von aromatischen Methoxycarbonsäuremethylestern.
ATE217641T1 (de) Tränk- und überzugspolyesterharzlösungen und deren verwendung
IT1237785B (it) Procedimento per la risoluzione ottica dell'acido treo-2-idrossi-3- (2'-ammino feniltio)-3-(4"-metossifenil) propionico
FR2703045B1 (fr) Procédé d'isomérisation d'acides carboxyliques.
EP0628638A3 (en) Process for the preparation of 2-amino-3-hydroxy-carboxylic acids.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19990614